Ratio Therapeutics Inc., a pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment and monitoring, has entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to partner and construct a radiopharmaceutical research and manufacturing facility in Salt Lake City, Utah, anticipated to be fully operational in the second half of 2027.

This 65,000 square foot manufacturing facility will support vertical integration of Ratio’s current and future pipeline of next-generation radiopharmaceuticals, with the capacity to efficiently scale manufacturing for future commercial needs as Ratio advances its candidates through clinical trials. The facility will enable end-to-end production capabilities while allowing the company to leverage the region’s robust radiopharmaceutical supply network and proximity to an international airport with central North American access, positioning Ratio to meet the complex supply chain demands of radiopharmaceutical development and commercialization.

“Ratio is excited to partner with Wasatch, who is ambitiously driving our field forward. With our pipeline advancing rapidly, securing a strategic manufacturing footprint is crucial to our long-term vision,” said Jack Hoppin, Ph.D., Chairman and CEO of Ratio. “This facility not only places us near potential suppliers, such as Nusano, but also provides the infrastructure needed to meet future manufacturing demands at commercial scale and represents a major step toward Ratio’s mission of developing and rapidly transitioning innovative radiopharmaceuticals to the clinic.”